First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
TRAXV
NASDAQ Global Select22.51
USD
+3.51
- -
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
TRAXV
(NASDAQ Global Select)
Recent
price
22.51
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued, clinical-stage biotechnology company focused on next-generation antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases; products and services include ANB033, a CD122 antagonist in a Phase 1b trial for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter completed a Phase 2b trial for rheumatoid arthritis; ANB101, a BDCA2 modulator in a Phase 1a trial; spinoff from AnaptysBio, Inc. in 2026 with planned listing and capital raise; securities trading impact and corporate actions tied to the spin-off and private placement. The company operates as part of the broader AnaptysBio corporate group structure in the biotechnology sector, with headquarters in the United States and operations intended to be global through strategic partnerships and potential collaborations across biotech and pharmaceutical markets. Founding year and primary corporate origin trace to the spin-off arrangement from AnaptysBio, with the new standalone entity commencing operations as of 2026. Subsidiaries or parent relationships align with the post-spin-off corporate framework, positioning First Tracks Biotherapeutics to advance immunology-targeted therapeutics through clinical development and potential commercialization partnerships.